VX-407 clinical trials

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

This study, called AGLOW, is looking at a new medicine called VX-407 for a kidney condition called Autosomal Dominant Polycystic Kidney Disease (ADPKD). It aims to see how it affects kidney size, if it's safe, and how the body handles it in specific patients with certain genetic markers.